IMMUNOASSAY FOR ANTIBODIES TO HTLV-III

Abstract: The invention is a diagnostic immunoassay which de­ tects antibodies specific for human T-cell lymphotropic virus-­ III (HTLV-III). The immunoassay utilizes two detection sys­ tems, each detection system designed to detect an antibody to a specific viral protein of HTVL-III.

Description: IMMUNOASSAY FOR ANTIBODIES TO HTLV-III BACKGROUND OF THE INVENTION Since human T-cell lymphotropic virus-III (HTLV-III) has been determined to be the probable causative agent of acquired immune deficiency syndrome (AIDS), several diagnostic immunoassays for antibodies to HTLV-III (anti-HTLV-III) have emerged. In U.S. Patent No. 4,520,113, three assays for anti-HTLV-III are described. These assays are, a strip radioinunoassay based on the Western Blot technique, an enzyme-linked immunosorbent assay (ELISA) and an indirect immunofluorescence assay. The problem with these previous assay methods is that they result in a small percentage of false positives due to non-specific reactors caused by techniques or reagents. One exan-;?le of such a ho-spcific reaction is the reaction between patients' samples and H-9 cellular protein materials in which the HTLV-III virus has been propagated for use as a reagent in the above-mentioned methods. Since the report of a positive anti-HTLV-III assay can be devastating to a patient, all reactive samples should be confirmed as true positives by at least two assay procedures. Presently, test samples are most commonly screened by an ELISA method. Repeatedly reactive specimens are then confirmed by the Western Blot procedure. The Western Blot procedure generally described by Towbin et al., Proc. Natl. Acad. Sci., 76: 4350 (1979), requires sodium dodecylsulfate (SDS)-polyacrylamide gel electrophoresis to separate HTLV-III viral proteins based on their molecular weight. The separated HTLV-III proteins are then transferred to a nitrocellulose sheet by a second electrophpretic procedure. The nitrocellulose sheet is cut into strips and reacted with the test sample and then with a second antibody such as a -radio-labeled goat anti-human IgG. The disadvantages of the Western Blot procedure for detecting anti-HTLV-III are that it requires subjective interpretation, it is both complex at a tempers times consuming to perform, and it is difficult to ad is ther control variations in the composition of the HTLV-III vital proteins and performance of the test. Therefore, a need exists for both a more specific immunoassay procedure for anti-HTLV-III and a simple second method for confirming repeatably reactive samples. SUMMARY OF THE INVENTION The invention is a competitive immunoassay method for detection of antibody to HTLV-III in a biological sample comprising at least two detection systems. One detection system comprises: a) coating a solid support with recombinant p24 protein expressed in E. coli; b) contacting the p24-coated solid support with the biological sample and anti-HTLV-III-p24 conjugated to a label; and c) detecting the label to determine the presence of anti-HTLV-III-p24 in the sample. The other detection system comprises: a) coating a solid support with recombinant p41 protein expressed in E. coli; b) contacting the p41-coated solid support with the biological sample and anti-HTLV-III-p41 conjugated to a label; and c) detecting the label to determine the presence of anti-HTLV-III-p41 in the sample. The detection of antibody to HTLV-III-p24 in the one detection system or antibody to HTLV-III-p41 in the other detection system, or both, indicates the presence of anti-HTLV-III in the sample. In a preferred embodiment, the solid support of one detection system is first coated with anti-HTLV-III-p24, and the solid support of the other detection system is first moated with anti-HTLV-III-p41 in order to enhance the coating of recombinant p24 and p41 proteins respectively on the solid supports. Biological samples which are easily tested by the method of the present invention include human and animal body fluids. Solid supports which can be used in the immunoassay of the invention include wells of reaction trays, test tubes, beads, strips or other solid supports which are well known to those skilled in the art. Labels which can be used in the above-described assay include enzymes, radioisotopes and fluorescent labels. Both polyclonal and monoclonal antibodies are useful as reagents in the present invention. Also, IgG and IgM antibodies may be used. In another preferred embodiment of the present invention, both detection systems of' the invention are located on the same solid support. DETAILED DESCRIPTION OF THE INVENTION The following examples are illustrative of the irnunassay of the present invention. EXAMPLE I. This example demonstrates an immunoassay for anti-HTLV-III in a human biological sample consisting of two solid phase detection systems. The first solid phase system comprises the following procedure: 1. A 1/4 inch polystyrene bead is first coated with anti-HTLV-III-p24 and then with the recombinant core structural protein of HTLV-III primarily encompassing the p24 region. The p24-coated bead is then contacted with 50 ul serum, plasma, or other biological sampl'e and 200 ul anti-HTLV-III-p24 conjugated to horseradish peroxidase (HRPO) for 1 to 24 hours and preferably 16 to 22 hours at a temperature range of 15 0C to 450C. The bead is then washed three times with 5.0 ml distilled water to remove any unbound sample or labeled antibody. 2. The washed bead is contacted with 300 ul of o-phenylenediamine-hydrogen peroxide solution which forms a yellow-colored product in the presence of horseradish peroxidase, and after incubating for approximately 30 minutes at room temperature, 1 ml of 1 N H2S04 is added. 3. Absorbance is read at 492 nm using a standard spectrophotometer. The second solid phase system comprises the following EMI4.1 1. A 1/4 nch polystyrene bead is first coated with anti-HTLV-III-p41 and then with the recombinant envelope protein of HTLV-III primarily encompassing the p41 region. The p41-coated bead is then contacted with 50 ul serum, plasma or other biological fluid and 200 ul anti-HTLV-III-p41 conjugated to horseradish peroxide (HRPO) for 1 to 24 hours and preferably 16 to 22 hours at a temperature range of 20 C to 450C. The bead is then washed three times with 5 ml distilled water to remove any unbound sample. 2. The washed bead is contacted with 300 ul of o-phenylenediamine-hydrogen peroxide solution which forms a yellow-colored product in the presence of horseradish peroxidase, and after incubating for approximately 30 minutes at room temperature, 1 ml of 1 N H2S04 is added. 3. Absorbance is read at 492 nm using a standard spectrophotometer. In each detection system, the antibody of interest (anti-HTLV-III-p24 and anti-HTLV-III-p41) competes with the corresponding labeled antibody (anti-HTLV-III-p24-HRPO and anti HTLV-III-p41-HRPO) for a number of binding sites on the coated bead. Therefore, the intensity of color developed in each detection system is inversely related to the amount of anti-HTLV-III-p41 and anti-HTLV-III-p24 in the sample. A positive reaction in either detection system or both indicates a positive test for anti-HTLV-III. EXAMPLE II. This example demonstrates the specificity of the present invention. Serum samples from patients with AIDS, patients with lymphadenopathy syndrome (LAS), a condition which often precedes the development of full-blown AIDS and normal subjects were tested with the immunoassay described in Example I (Assay A), with a commercially available enzyme immunoassay for anti-HTLV-III, Abbott Laboratories, North Chicago, Illinois (Assay B) and by the Western Blot procedure (Assay C). All 91 of the AIDS patients' samples were positive by the Assay B procedure; 90 of 91 samples were positive by the Assay C procedure; and all samples were positive utilizing the Assay A procedure of the present invention (Table 1). In the first detection system of the invention (which detects antibodies to HTLV-III-p24) 10 of 41 samples from individuals with AIDS were positive, while all 91 samples were positive utilizing the second detection system of the invention (which detects antibodies to HTLV-III-p41). Since a positive reaction in either detection system indicates a positive result, all samples were defined as positive by the inventive assay procedure. All 62 samples from LAS patients were positive utilizing Assays A, B and C. None of the 375 samples from normal subjects had detectable antibody by Assays A, B and C. Thus, utilizing the assay of the present invention, all sera from AIDS patients and patients with LAS were detected as positive, while none of the sera from normal subjects were detected as positive. EXAMPLE III. Samples of serum or plasma from blood donors which were repeatedly reactive in a commercially available enzyme immunoassay for anti-HTLV-III (Abbott Laboratories, North Chicago, Illinois), were tested with the present invention and by the Western Blot procedure (Table 2). Among these repeatedly reactive samples, 232 samples were negative by Western Blot and by the double detection system assay of the present invention. One sample which had an undeterminable reaction by the Western Blot procedure, was positive in the assay of the present invention, being reactive in both detection systems. Of the 118 samples confirmed positive by the Western Blot procedure, all 118 were also positive utilizing the present invention. TABLE 1 Positive/Total - - Assay A Sables Anti-p24 Anti-p41 Assay B Assay C Normal Subjects 0/375 0/375 0/375 0/375 AIDS 10/41 91/91 91/91 90/91 LAS 10/14 62/62 62/62 62/62 TABLE 2 Comparison of Western Blot Procedure vs. Double Detection System Assay Samples Positive in Positive in Positive in (repeatedly reactive Either or Both System 1 System 2 n = 351) Detection Systems (anti-p24) (anti-p41) Western Blot negative 0/232 0/232 0/232 (n = 232) Western Blot positive 118/118 102/118 115/118 (n = 118) Western Blot undeter- 1/1 1/1 1/1 minable (n = 1) The identification of biological samples which are positive for anti-HTLV-III is important in the screening and protection of human blood supplies. This assay enables a quick screening procedure as well as a second confirmatory assay for detecting true positive samples for antirH.TLV-III. While specific examples have been given to illustrate the invention, it is to be understood that those skilled in the art will recognize variations without departing from the spirit and scope of the invention.

Claims: CLAIMS: 1. A method for detecting antibody to HTLV-III comprising at least two detection systems, one detection system comprising: a. coating a solid support with recombinant p24 protein expressed in E. coli; b. contacting the p24-coated solid support with a biological sample and anti-HTLV-III-p24 conjugated to a label; and c. detecting the label to determine the presence of anti-HTLV-III-p24 in the sample; and the other detection system comprising: d. coating a solid support with recombinant p41 protein expressed in E. coli; e. contacting the p41-coated solid support with the biological sample and anti-HTLV-III-p41 conjugated to a label; and f. detecting the label to determine the presence of anti-HTLV-III-p41 in the sample; wherein the presence of anti-HTLV-III in either or both detection systems indicates the presence of anti-HTLV-III in the sample. 2. The method of Claim 1 wherein the solid support of step a. is first coated with anti-HTLV-III-p24 and then with the recombinant p24 protein; and the solid support of step d. is first coated with anti-HTLV-III-pl and then with the recombinant p41 protein. 3. The method of Claim 1 wherein the labels of the two detection systems are enzymes, radioisotopes or fluorescent labels. 4. The method of Claim 1 wherein both detection systems are located on one solid support. 5. An immunoassay for detecting antibody to HTLV-III in a biological sample comprising at least two detection systems, the first detection system comprising: a. a solid support coated with recombinant p24 protein expressed in E. coli; and b. anti-HTLV-III-p24 conjugated to a label; and the second detection-system comprising: c. a solid support coated with recombinant p41 protein expressed in E. coli; and d. anti-HTLV-III-p41 conjugated to a label. 6. The immunoassay of Claim 7 wherein the solid support of the first detection system is first coated with anti-HTLV-III-p24 and then coated with the recombinant p24 protein, and the solid support of the second detection system is first coated with anti-HTLV-III-p41 and then coated with the recombinant p41 protein. 7. The immunoassay of Claim 7 wherein the labels of the fir second detection systems are enzymes, radioisotopes or fluorescent labels. 8. The immunoassay of Claim 7 wherein the first and second detection systems are located on the same solid support. 9. A method for detecting antibody to HTLV-III comprising at least two detection systems, the first detection system comprising: a. first coating a polystyrene bead with anti-HTLV-III-p24 and then with recombinant p24 protein expressed in E coli; b. contacting the bead with a biological sample and anti-HTLV-III-p24 conjugated to horseradish peroxidase; c. washing the bead; d. contacting the washed bead with o-phenyleneiamine-hydrogen peroxide solution to form a yellow-colored product; and e. detecting the absorbance of the yellow-colored product to determine the presence of anti-HTLV-III-p24 in the sample; and the second detection system comprising: f. first coating a polystyrene bead with anti-HTLV-III-p41 and then with recombinant p41 protein expressed in E. coli; g. contacting the bead with a biological sample and anti-HTLV-III-p41 conjugated to horseradish peroxidase; h. washing the bead; i. contacting the washed bead with o-phenylenediamine-hydrogen peroxide solution to form a yellow-colored product; and j. detecting the absorbance of the yellow-colored product to determine the presence of anti-HTLV-III-p41 in the sample. 10. The method of Claim 13 wherein the first and second detection systems are located on the same bead.

Inventors: DAWSON, GEORGE L.
Applicants: ABBOTT LABORATORIES
Application year: 1986
Main classification: G01N33
IPC codes: C12Q1, G01N33